

OSTEOPOROSIS REFERRAL FORM

FAX: 888 889 7129

TOLL FREE: 844 233 7279

CEDRA							CEDR	:ASPECIAL	TY.COM
PATIENT INFORMATION									
Patient Name:		OB:	Prefe	rred Phon	e:				
SSN#:			Lang	guage:	English	Other			
Address:			Sex:	Male	Female	Height:	Weight:	lbs	kg
City:	State			vn Allergie					
* PLEASE FAX FRONT/BACK COPY OF PRESCRIBER INFORMATION	PHARMACY BENEFIT O	CARD, MEDIC	CAL INSURANCE CA	ARD, NOTES	S, LABS & TES	TS WITH THE PRE	SCRIPTION TO EX	(PEDITE PROCI	SSING *
Prescriber Name:			DFA#:		NPI#		Tax ID#:		
Address:			Phone:			E-mail:			
City:	State:	Zip:	Key Contact:			Phone:		Fax:	
STATUS UPDATE PREFERENCE: Phone	Text Fax	E-mail:							
DIAGNOSIS/CLINICAL INFORMATION Diagnosis M88.9 Paget's Disease M80.80 M80.88 Pathological Fracture of Ve Date of Diagnosis:	Unspecified Osteoportebrae M80.85 I		81.0 Postmenopa I Fracture of Neck				Drug-induced C order of bones	Osteoporosis M94.9 of c	cartilage
Patient Evaluation - General Treatment History: New to this Medi NOTE: If continuing on FORTEO®, what			(FORTE	⊃® can be	e taken for c	maximum of 2	24 months)		
Patient Evaluation – Osteoporosis Lowest Dexa T-Score: Fracture Site (if approp):			e of Dexa: Date of fracture:						
Prior Failed Medication(s)	Le	ength of Tred	atment			Reasons for	r Discontinuatior	1	

EDICATION	DOSE/STRENGTH	SIG	QTY.	REFIL
ACTONEL®	mg tablets			
BONIVA®	Prefilled Syringe (3mg/3ml) 150 mg tablet	Inject 3mg IV over 15-30 seconds every 3 months 1 tablet once monthly, taken at the same date each month	1 Syringe (3mg/3ml)	
FORTEO®	Pen (600ug/2.4ml) Delivery Device	Inject 20mcg (0.08ml) SQ daily (FORTEO® can be taken for a maximum of 24 months)	1 Pen (600ug/2.4ml)	
	Complimentary Needles 4mm 32G 5mm 31G 8mm 31G	Use with FORTEO® Delivery Device as directed	30	
FOSAMAX®	35 mg tablets 70 mg tablets	1 tablet once weekly		
PROLIA®	Prefilled Syringe (60mg/ml)	Inject 60mg SQ once every 6 months	1 Pen (60mg/ml)	
TYMLOS™	Prefilled Pen 3120 mcg/1.56 mL (2000 mcg/mL)	Recommended dose is 80 mcg subcutaneously once daily; patients should receive supplemental calcium and vitamin D if dietary intake is inadequate. Administer as a subcutaneous injection into periumbilical region of abdomen. Administer initially where the patient can sit or lie down in case symptoms of orthostatic hypotension occur.	1 Syringe (3mg/3ml)	
ZOLEDRONIC ACID	Vial (5mg/100ml)	Infuse 5mg IV, over no less than 15 minutes, every year Infuse 5mg IV, over no less than 15 minutes, every 2 years	1 Vial (5mg/100ml)	

COMMENTS:

INJECTION TRAINING				
Patient has received pen and injection training	Enroll patient in r	manufacturer-sponsc	scred training program	
Date Medication Needed:	Deliver To:	Patient Home	MD Office	
Prescriber Signature: (Please sign and date by Your signature authorizes Cedra Pharmacy to act on you	oelow.) ur behalf to obtain	prior authorization for t	or the prescribed medications. We will also pursue available copay and financial assistance on behalf of your patients.	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

374_OsteoRef100-03NY-B

Dispense as written "DAW"



Substitution Permissible